Hilltop BioSciences — A Veterinary Biotech To Help Pets Heal

Bringing one of the first room temperature, easily accessible, and regenerative therapies to veterinary medicine

Bram Berkowitz
Apr 13 · 3 min read

The Problem

Veterinarians have many solutions to treat the symptoms of inflammation in the body. Those solutions, while effective, have long recovery times, inconsistent dosing, and lower efficacy rates. Despite current therapies, over $1B is lost each year in the equine industry due to injury or disease. Revenue is not as important for our dogs, but the quality of life and cost of care is. Of the 90M dogs in the U.S., 20M will have an injury each year that requires expensive treatment.

What The Company Does

Hilltop Bio’s revolutionary treatment allows veterinarians to have an off-the-shelf, effective product, that does not require a large capital investment or training. The products easily treat soft tissue injuries that would have likely required surgery or inflammatory diseases and pain medication and other therapies. This helps pets have a higher quality of life, while saving money for their owners. Hilltop Bio’s line of products contain a whole range of components including cytokines, exosomes, and many other proteins to help the body reduce certain inflammation and heal soft tissue injuries. Growing clinical research demonstrates successful restoration of function in the treated animals. Products have shown to reduce recovery times from injuries and reduce the risk for re-injury.

Market

The veterinary care market is a large, $42B industry. Hilltop Bio is first focused on sports medicine in horses and believes the market opportunity is $800M. After successful penetration of the equine market, Hilltop Bio will focus efforts on a canine product. Estimated market opportunity for canine pain/sports medicine is $1.2B. Competitors include Pro-Stride, Arthrex Angel Systems, and other platelet rich plasma (PRP) companies. Competitive regenerative therapies are not off the shelf or room temperature.

Business Model

Hilltop Bio is a B2B company selling directly to veterinarians. Those veterinarians then sell the treatment and product to the end user (horse or dog owners). The veterinarians can purchase as needed, or keep the product on the shelf or in the trucks to treat the animal immediately after injury.

Traction

Hilltop Bio products are available in the market currently. Roughly 96% of the veterinarians that have purchased and used the products make repeat purchases monthly and increase their order amount each month. Sales have continued an upward trend despite COVID and Hilltop Bio has continued to expand on treatment indications.

Founding Team Background

Co-Founder, CEO, and President Amanda Drobnis previously worked for PetSmart in marketing and event planning, and then a small human regenerative therapy company in sales and marketing. Mark Williams, the co-founder and VP of business development, has spent more than 20 years in veterinary medicine. He first started sales in medical devices for veterinarians and then has slowly moved over to bring new products to market from oversees. Chief Veterinary Officer Dr. David Dutton has more than 20 years of experience as an equine surgeon and treating competitive horses in Texas. In his years in practice, he has tried many regenerative therapies and has focused on birth tissue therapies for quite some time. Dutton is also a professor of equine surgery at Texas Tech.

The Ask

Hilltop Bio is looking for for introductions to marketing/scaling advisors who are familiar with the veterinary industry. They are always looking for introductions to potential customers including equine or canine veterinarians. Hilltop Bio has an open funding round and is looking for intros to investors around the country with an interest in biotech and animal health. Connect With The Hilltop Bio Team.

Storied

The storytelling platform for startups building in New England.

Bram Berkowitz

Written by

Writing about banks, stocks, and startups. Frequently published in The Motley Fool and Rhode Island Inno. Co-founder of The Buzz.

Storied

Storied

The storytelling platform fueling the next generation of founders in New England.

Bram Berkowitz

Written by

Writing about banks, stocks, and startups. Frequently published in The Motley Fool and Rhode Island Inno. Co-founder of The Buzz.

Storied

Storied

The storytelling platform fueling the next generation of founders in New England.

Medium is an open platform where 170 million readers come to find insightful and dynamic thinking. Here, expert and undiscovered voices alike dive into the heart of any topic and bring new ideas to the surface. Learn more

Follow the writers, publications, and topics that matter to you, and you’ll see them on your homepage and in your inbox. Explore

If you have a story to tell, knowledge to share, or a perspective to offer — welcome home. It’s easy and free to post your thinking on any topic. Write on Medium

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store